TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
The CDC’s 2026 Antimicrobial Resistance Threats Report lists 19 pathogens and estimates they cause 9.7 million infections and 50,800 deaths annually in the United States. Four drug-resistant pathogens are classified as urgent threats, while C. difficile moved down to serious and six pathogens were added to a watch list.
The CDC’s 2026 antimicrobial-resistance report identifies 19 pathogens whose threat levels range from concerning to urgent and estimates they cause 9.7 million infections and 50,800 deaths annually in the United States. Four drug-resistant pathogens received the agency’s top-tier urgent classification, while six additional pathogens were placed on a watch list.
The four urgent threats are Candida auris (also called Candidozyma auris), carbapenem-resistant Acinetobacter, carbapenem-resistant Enterobacterales and drug-resistant Neisseria gonorrhoeae. The CDC’s overall figures apply to the pathogens covered by the report; they are not a death toll attributed only to those four urgent threats.
The report describes changes in both threat levels and monitoring. Drug-resistant N. meningitidis was classified as a serious threat requiring prompt, sustained action. Drug-resistant dermatophytes, drug-resistant Haemophilus influenzae and nontuberculous mycobacteria are among pathogens added to the watch list, which tracks potential threats with uncertain disease burdens.
Clostridioides difficile moved from urgent to serious. The report links the change in part to infection-prevention efforts and a decline in cases since 2011. That lower classification does not mean the pathogen has ceased to pose a serious threat.
Why Resistant Infections Matter
Antimicrobial resistance can make infections harder to treat, with consequences beyond the infection itself. Wendy Armstrong, president of the Infectious Diseases Society of America, said resistant infections can prolong hospital stays and increase health-care costs. She also warned that they can make it more difficult for clinicians to safely provide care such as chemotherapy, organ transplants and surgery.
The report’s estimates show the scale of the problem across the pathogens it tracks, but the risks differ by organism and patient. The CDC report says some threats are especially relevant to people receiving hospital or nursing-home care, while drug-resistant gonorrhea can restrict treatment choices for a common sexually transmitted infection.
Armstrong called for passage of the PASTEUR Act, which would establish a federal program to support development of antimicrobial drugs for threatening infections. The source report says versions of the bill remained stalled in congressional committees at the time of publication.
Products Worth Considering
Withings BPM Connect Wi-Fi and Bluetooth Blood Pressure Monitor
Garmin Forerunner 570 GPS Running Smartwatch, 47mm, Aluminum, Black
Fitbit Sense 2 Smartwatch – Blue Mist / Pale Gold
As an affiliate, we earn on qualifying purchases.
How the Threat List Changed
The CDC’s updated report groups pathogens by threat level and separately identifies organisms on a watch list. The categories distinguish established concerns from potential threats where the disease burden is not yet clear. The report names 19 pathogens across its threat categories and six on the watch list; those counts should not be confused with the four organisms designated urgent.
Among the report’s examples, U.S. C. auris cases rose from 48 in 2016, when cases were first reported, to 4,523 in 2023. For 2023, the report attributes 9,497 hospitalizations and an estimated 817 deaths to carbapenem-resistant Acinetobacter, and 14,878 hospitalizations and an estimated 1,252 deaths to carbapenem-resistant Enterobacterales.
Drug-resistant N. gonorrhoeae caused an estimated 787,000 U.S. infections in 2023. The report says 55.4% of gonorrhea cases that year were resistant to at least one of six antibiotics or had elevated minimum inhibitory concentrations. The FDA approved gepotidacin and zoliflodacin in 2025 as new antibiotics for gonorrhea, according to the source report.
““These numbers are alarming by any measure, but they are particularly sobering when infectious diseases physicians connect real patients with these statistics in their everyday experience.””
— Wendy Armstrong, president of the Infectious Diseases Society of America
What the Estimates Do Not Show
The 50,800 annual deaths and 9.7 million infections are CDC estimates for the report’s listed pathogens together. The supplied report does not break down those totals by pathogen, and the figures should not be read as deaths caused by the four urgent threats alone. The cited organism-specific hospitalization and death figures are for 2023, while the overall figures are presented as annual estimates.
The watch-list designation reflects uncertainty about the disease burden of potential threats, not a finding that those pathogens already cause a known number of infections or deaths. The supplied material does not give detailed methods behind the overall estimates or a full pathogen-by-pathogen breakdown of the 19 threats. It is also unclear from the report summary how quickly the new categories may change as surveillance data develop.
Surveillance and Drug Development
The CDC’s report puts the newly listed and reclassified pathogens on the public-health agenda, with watch-list organisms requiring further monitoring as evidence develops. The figures cited for individual pathogens are from 2023; the supplied material does not set out a schedule for the next report or specify when newer organism-level estimates will be released.
Policy action remains another open development. Armstrong has urged Congress to pass the PASTEUR Act, but the source report says its House and Senate versions were stalled in committee. Whether lawmakers advance either version, and what funding or drug-development program might follow, remains unresolved.
Key Questions
What does the CDC estimate the listed pathogens cause?
The CDC estimates the pathogens covered by its report cause 9.7 million infections and 50,800 deaths annually in the United States.
Which pathogens are classified as urgent threats?
The four urgent drug-resistant threats are Candida auris, carbapenem-resistant Acinetobacter, carbapenem-resistant Enterobacterales and drug-resistant Neisseria gonorrhoeae.
Why did C. difficile move to a lower threat category?
The report says C. difficile moved from urgent to serious, in part because infection-prevention measures have helped reduce cases since 2011. It remains classified as a serious threat.
What is the CDC’s watch list?
It tracks pathogens considered potential threats when their disease burden is uncertain. The report adds six pathogens to the watch list, including drug-resistant dermatophytes and drug-resistant Haemophilus influenzae.
Are the 50,800 deaths attributed only to the four urgent threats?
No. The figure is an estimate for the pathogens covered across the report. The supplied report summary does not break the total down by pathogen.
Source: medpagetoday.com
